MX366118B - Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. - Google Patents

Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.

Info

Publication number
MX366118B
MX366118B MX2015013911A MX2015013911A MX366118B MX 366118 B MX366118 B MX 366118B MX 2015013911 A MX2015013911 A MX 2015013911A MX 2015013911 A MX2015013911 A MX 2015013911A MX 366118 B MX366118 B MX 366118B
Authority
MX
Mexico
Prior art keywords
paracetamol
celecoxib
treatment
inflammatory pain
synergistic combination
Prior art date
Application number
MX2015013911A
Other languages
English (en)
Other versions
MX2015013911A (es
Inventor
Fernando Cantú Medellin Jorge
Original Assignee
More Pharma Corp S De R L De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52279400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366118(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by More Pharma Corp S De R L De C V filed Critical More Pharma Corp S De R L De C V
Publication of MX2015013911A publication Critical patent/MX2015013911A/es
Publication of MX366118B publication Critical patent/MX366118B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe y reclama una combinación de paracetamol y celecoxib que en cantidades específicas generan una potenciación analgésica contra el dolor de tipo inflamatorio. Específicamente, la invención se refiere una combinación sinergística de entre 375 a 500 mg de paracetamol y de entre 50 a 100 mg de celecoxib útil para el tratamiento de dolor inflamatorio en animales y seres humanos, así como el uso de dichos principios activos en las cantidades indicadas en la preparación de combinaciones farmacéuticas sinérgicas.
MX2015013911A 2013-07-11 2014-07-11 Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. MX366118B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2013/055710 WO2015004505A1 (es) 2013-07-11 2013-07-11 Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
PCT/IB2014/063019 WO2015004634A2 (es) 2013-07-11 2014-07-11 Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio

Publications (2)

Publication Number Publication Date
MX2015013911A MX2015013911A (es) 2015-12-08
MX366118B true MX366118B (es) 2019-06-27

Family

ID=52279400

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013911A MX366118B (es) 2013-07-11 2014-07-11 Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.

Country Status (8)

Country Link
CL (1) CL2015003211A1 (es)
CR (1) CR20160021A (es)
CU (1) CU24440B1 (es)
DO (1) DOP2016000008A (es)
EC (1) ECSP16005679A (es)
MX (1) MX366118B (es)
PE (2) PE20160239A1 (es)
WO (2) WO2015004505A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4534077A1 (en) 2023-10-05 2025-04-09 Laboratorios Silanes, S.A. de C.V. Composition comprising cyanocobalamin, pyridoxine, thiamine, pregabalin and celecoxib
EP4534076A1 (en) 2023-10-05 2025-04-09 Laboratorios Silanes, S.A. de C.V. Celecoxib - acetaminophen combination of improved stability and procedure for the preparation thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147780B2 (en) * 2020-02-24 2021-10-19 Algia Pharma, Llc Multidrug pain management package

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163637A0 (en) * 2002-02-19 2005-12-18 Adcock Ingram Ltd Pharmaceutical combinations of cox-2 inhibitors and opiates
GB0423103D0 (en) * 2004-10-19 2004-11-17 Boots Healthcare Int Ltd Therapeutic agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4534077A1 (en) 2023-10-05 2025-04-09 Laboratorios Silanes, S.A. de C.V. Composition comprising cyanocobalamin, pyridoxine, thiamine, pregabalin and celecoxib
EP4534076A1 (en) 2023-10-05 2025-04-09 Laboratorios Silanes, S.A. de C.V. Celecoxib - acetaminophen combination of improved stability and procedure for the preparation thereof

Also Published As

Publication number Publication date
CU24440B1 (es) 2019-09-04
CU20160002A7 (es) 2016-06-29
CR20160021A (es) 2016-04-08
DOP2016000008A (es) 2016-03-15
WO2015004505A1 (es) 2015-01-15
ECSP16005679A (es) 2017-08-31
WO2015004634A2 (es) 2015-01-15
PE20170305A1 (es) 2017-04-21
CL2015003211A1 (es) 2016-04-29
WO2015004634A3 (es) 2015-04-09
PE20160239A1 (es) 2016-05-13
MX2015013911A (es) 2015-12-08

Similar Documents

Publication Publication Date Title
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2015004644A (es) Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12015502282A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
PH12013500371A1 (en) Therapeutic agent for pain
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
MX366118B (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
AU2014353885A8 (en) Prevention and treatment of toxicosis
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
IN2013MU03428A (es)
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2016012553A (es) Composiciones farmaceuticas de mazindol con metformina para perdida de peso.
AR099681A1 (es) Composiciones de grapiprant y métodos para su utilización
UA101054C2 (en) Veterinary preparation
MX2012006194A (es) Composiciones analgesicas que comprenden quercetina mas ketorolaco.

Legal Events

Date Code Title Description
FG Grant or registration